Xencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast and Conference Call on February 28, 2017 Read more about Xencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast and Conference Call on February 28, 2017
IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis Read more about IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis
Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference Read more about Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference
Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock Read more about Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
Xencor, Inc. Prices Public Offering of Common Stock Read more about Xencor, Inc. Prices Public Offering of Common Stock
Xencor, Inc. Announces Proposed Public Offering of Common Stock Read more about Xencor, Inc. Announces Proposed Public Offering of Common Stock
Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting Read more about Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting
Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and Additional Bispecific Antibody Candidates at Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting Read more about Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and Additional Bispecific Antibody Candidates at Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
Xencor Reports Third Quarter 2016 Financial Results Read more about Xencor Reports Third Quarter 2016 Financial Results
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
